BioMarin Pharmaceutical Inc. buy UBS Group AG
Start price
30.10.24
/
50%
€62.34
Target price
30.10.25
€97.65
Performance (%)
-28.01%
End price
31.10.25
€44.88
Summary
This prediction ended on 31.10.25 with a price of €44.88. The price of BioMarin Pharmaceutical Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -28.01%. UBS_Group_AG has a follow-up prediction for BioMarin Pharmaceutical Inc. where he still thinks BioMarin Pharmaceutical Inc. is a Buy. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| BioMarin Pharmaceutical Inc. | -5.167% | -5.167% | -21.805% |
| iShares Core DAX® | -0,68 % | -4,85 % | 1,94 % |
| iShares Nasdaq 100 | -0,03 % | 2,86 % | 18,90 % |
| iShares Nikkei 225® | -0,54 % | -5,02 % | 28,15 % |
| iShares S&P 500 | -0,21 % | 0,92 % | 13,69 % |
Comments by UBS_Group_AG for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $104.00 to $106.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
In the thread Trading BioMarin Pharmaceutical Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Current prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€51.06
05.08.25
05.08.25
€98.62
05.08.26
05.08.26
-4.90%
17.03.26
17.03.26
Stopped prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€65.70
20.02.25
20.02.25
€108.05
20.02.26
20.02.26
-18.54%
21.02.26
21.02.26